Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News InflaRx NV IFRX

Healthcare Biotechnology
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IFRX)

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

GlobeNewswire 3 days ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

GlobeNewswire September 3, 2024

InflaRx Announces Participation in September Investor Events

GlobeNewswire August 27, 2024

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 8, 2024

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

GlobeNewswire August 1, 2024

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

GlobeNewswire July 30, 2024

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

GlobeNewswire June 24, 2024

InflaRx Hosts R&D Event Highlighting the Promise of INF904

GlobeNewswire June 5, 2024

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

GlobeNewswire May 21, 2024
View More News ››

Opinion & Analysis (NDAQ:IFRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IFRX)

InflaRx Presents New Preclinical Findings for INF904 at the

News; $IFRX InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human DiseasesJENA...
whytestocks - September 3, 2024

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Spo

Breaking News: $IFRX InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host...
whytestocks - June 24, 2024

New COVID Studie Q 1/22

It should also be noted that our other study is now being continued. It would not be published properly yet. The continuation of this...
Sokratesaes86 - January 9, 2022

Ab very very BiG Market

Inflarx sepsis drug. Cost in the US alone. Values from then are now much higher. In 2011, sepsis topped the list of the most cost...
Sokratesaes86 - January 9, 2022

Inflarex Countdown to Party

Inflarex IFRX Germany course 3.80 Biopharma Further decision studies will be completed in the 1st half of 2022 including: Vilobelimab is...
Sokratesaes86 - January 9, 2022

ifrx --covid application

https://www.inflarx.de/Home/Investors/Press-Releases.html
securitynnmotn - July 21, 2020
View more Bullboard ››

Cascadia Minerals Ltd

Cascadia Minerals Ltd

Cascadia is a Canadian junior mining company focused on exploring for copper and gold in the Yukon and British Columbia ...
View More »